

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

| | Item No | Recommendation |
|---------------------------|---------|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found |
| Introduction | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses |
| Methods | | |
| Study design | 4 | Present key elements of study design early in the paper |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| Bias | 9 | Describe any efforts to address potential sources of bias |
| Study size | 10 | Explain how the study size was arrived at |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses |
| Results | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) |
| Outcome data | 15* | Report numbers of outcome events or summary measures over time |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |

- Kommentarad [Hd1]:** 'A cohort study of' is stated in the title.
- Kommentarad [Hd1R2]:** Line 1
- Kommentarad [Hd2]:** In the method section of the abstract, a summary is given of what was done (registry data, analyses). The result section of the abstract states what was found
- Kommentarad [Hd2R2]:** Lines 18-30.
- Kommentarad [Hd3]:** In the introduction, the scientific background and rationale is reported.
- Kommentarad [Hd3R2]:** Lines 38-61
- Kommentarad [Hd4]:** Introduction: 'The aim of our study was to analyze the association of specific hospital characteristics defined as volume, type, and referral for revision, with frequency and reasons for revision.'
- Kommentarad [Hd4R2]:** Lines 59-61
- Kommentarad [Hd5]:** The method section starts with an explanation of being a cohort study and states that data from the dutch registry was used.
- Kommentarad [Hd5R2]:** Lines 65-67.
- Kommentarad [Hd6]:** Some of these are not relevant for the study, i.e. exposure, follow-up. The study period (2007-2022) is mentioned.
- Kommentarad [Hd6R2]:** Line 66
- Kommentarad [Hd7]:** Eligibility criteria are defined as 'all primary and revision UKAs' the sources and method of selection of participants should be self explanatory due to using registry data. Methods of follow-up are not applicable for this study.
- Kommentarad [Hd7R2]:** Lines 65-66
- Kommentarad [Hd8]:** Not applicable for this study
- Kommentarad [Hd9]:** All outcomes are defined. Exposures do not feel relevant because the study looked at all patients with UKA.
- Kommentarad [Hd9R2]:** Lines 74-94
- Kommentarad [Hd10]:** Potential bias is mostly related to the limitations of a registry based study. This is mentioned in the ... [1]
- Kommentarad [Hd10R2]:** Lines 281-286
- Kommentarad [Hd11]:** Flow chart was included at the ... [2]
- Kommentarad [Hd11R2]:** Lines 139-142; Lines 396-398
- Kommentarad [Hd12]:** Quantitative variables were expl ... [3]
- Kommentarad [Hd12R2]:** Lines 74-94
- Kommentarad [Hd13]:** Not applicable
- Kommentarad [Hd14]:** Addressing of missing data was ... [4]
- Kommentarad [Hd14R2]:** Line 97
- Kommentarad [Hd15]:** Not applicable
- Kommentarad [Hd16]:** Not applicable
- Kommentarad [Hd17]:** Reported at the start of the result ... [5]
- Kommentarad [Hd17R2]:** Lines 139-142; Lines 396-397
- Kommentarad [Hd18]:** Reported at the start of the result ... [6]
- Kommentarad [Hd18R2]:** Lines 139-142
- Kommentarad [Hd19]:** We have a patient flowchart
- Kommentarad [Hd19R2]:** Lines 396-397
- Kommentarad [Hd20]:** Table 1 patient and prosthesis ... [7]
- Kommentarad [Hd20R2]:** Lines 399-401
- Kommentarad [Hd21]:** The number of participants and n ... [8]
- Kommentarad [Hd21R2]:** Lines 139-142; Lines 396-397.
- Kommentarad [Hd22]:** Follow-up times are summarized ... [9]
- Kommentarad [Hd22R2]:** Lines 399-401

| | | |
|--------------------------|----|--|
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses |
| Discussion | | |
| Key results | 18 | Summarise key results with reference to study objectives |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results |
| Other information | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |

Kommentarad [Hd23]: The 8th alinea in the discussion is about limitations

Kommentarad [Hd23R2]: Lines 281-286.

Kommentarad [Hd24]: Generalisability is discussed after the limitations.

Kommentarad [Hd24R2]: Lines 287-291.

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [1] Kommenterad [Hd10] | Hen drik | 2026-01-27 18:07:00 |
|---------------------------------------|-----------------|----------------------------|

Potential bias is mostly related to the limitations of a registry based study. This is mentioned in the discussion.

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [2] Kommenterad [Hd11] | Hen drik | 2025-12-19 14:36:00 |
|---------------------------------------|-----------------|----------------------------|

Flow chart was included at the beginning of the results section.

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [3] Kommenterad [Hd12] | Hen drik | 2026-01-27 18:08:00 |
|---------------------------------------|-----------------|----------------------------|

Quantitative variables were explained in the method section.

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [4] Kommenterad [Hd14] | Hen drik | 2026-01-27 18:11:00 |
|---------------------------------------|-----------------|----------------------------|

Addressing of missing data was explained in the method section

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [5] Kommenterad [Hd17] | Hen drik | 2026-01-27 18:13:00 |
|---------------------------------------|-----------------|----------------------------|

Reported at the start of the result section and in figure 1 patient flowchart

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [6] Kommenterad [Hd18] | Hen drik | 2026-01-27 18:14:00 |
|---------------------------------------|-----------------|----------------------------|

Reported at the start of the result section.

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [7] Kommenterad [Hd20] | Hen drik | 2025-12-22 11:23:00 |
|---------------------------------------|-----------------|----------------------------|

Table 1 patient and prosthesis characteristics

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [8] Kommenterad [Hd21] | Hen drik | 2025-12-22 11:27:00 |
|---------------------------------------|-----------------|----------------------------|

The number of participants and missing data are mentioned at the start of the result section and in figure 1 patient flowchart.

| | | |
|---------------------------------------|-----------------|----------------------------|
| Sida 1: [9] Kommenterad [Hd22] | Hen drik | 2025-12-22 11:30:00 |
|---------------------------------------|-----------------|----------------------------|

Follow-up times are summarized in figure 1.